# Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

> **NCT05542693** · PHASE2 · UNKNOWN · sponsor: **Azidus Brasil** · enrollment: 300 (estimated)

## Conditions studied

- COVID-19
- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** RNA MCTI CIMATEC HDT 5µg
- **BIOLOGICAL:** RNA MCTI CIMATEC HDT 10µg
- **BIOLOGICAL:** Covishield® - AstraZeneca
- **BIOLOGICAL:** Comirnaty® - Pfizer

## Key facts

- **NCT ID:** NCT05542693
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2023-03
- **Final completion:** 2023-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05542693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05542693, "Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05542693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*